NASOPHARYNGEAL CARCINOMA
Clinical trials for NASOPHARYNGEAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new NASOPHARYNGEAL CARCINOMA trials appear
Sign up with your email to follow new studies for NASOPHARYNGEAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cancer drug PRO1160 tested in advanced cancers – trial ends early
Disease control TerminatedThis study tested a drug called PRO1160 in people with advanced kidney cancer, nasopharyngeal cancer, or non-Hodgkin lymphoma. The goal was to find a safe dose and see if the drug shrinks tumors. The trial was stopped early, so results are limited.
Matched conditions: NASOPHARYNGEAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Experimental cancer drug TAK-500 tested in 61 patients – study halted early
Disease control TerminatedThis early-phase trial tested an experimental drug called TAK-500, alone or with the immunotherapy pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The stud…
Matched conditions: NASOPHARYNGEAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Cancer combo trial halted before full results
Disease control TerminatedThis early-stage trial tested a combination of two drugs, APG-1387 and toripalimab, in 40 people with advanced solid tumors including colorectal, nasopharyngeal, and lung cancers. The goal was to find a safe dose and see if the combination could control the disease. However, the …
Matched conditions: NASOPHARYNGEAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental cancer drug trial ends early
Disease control TerminatedThis early-stage study tested an experimental drug called INCB099318 in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and how the body processes it. The study was terminated early, so results are…
Matched conditions: NASOPHARYNGEAL CARCINOMA
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC